Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF – Get Free Report) gapped up before the market opened on Monday. The stock had previously closed at $14.95, but opened at $16.00. Ono Pharmaceutical shares last traded at $16.00, with a volume of 192 shares.
Analyst Ratings Changes
Separately, Zacks Research downgraded Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. One investment analyst has rated the stock with a Hold rating. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.
View Our Latest Stock Analysis on OPHLF
Ono Pharmaceutical Stock Performance
The firm has a fifty day moving average of $15.18 and a 200 day moving average of $14.86.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.
Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Taiwan Semiconductor Flexes Pricing Power on AI’s Frontline
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
